Xin Lang Cai Jing·2026-03-27 06:53Core Viewpoint - Tiger Med has seen a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, indicating a positive market sentiment towards the company [1][4]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][4]. - The main business segments include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][4]. - Revenue composition is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][4]. Fund Holdings - The Huashan National Bio-Medical ETF (159508) has increased its holdings in Tiger Med by 12,600 shares, bringing the total to 39,400 shares, which constitutes 5.58% of the fund's net value, making it the fourth-largest holding [2][5]. - The fund was established on June 29, 2023, with a current size of 40.08 million CNY. Year-to-date, it has experienced a loss of 6.74%, ranking 4,743 out of 5,563 in its category [2][5]. Fund Manager Performance - The fund manager, Su Qingyun, has a tenure of 9 years and 101 days, managing assets totaling 10.863 billion CNY. The best fund return during this period is 102.21%, while the worst return is -62.44% [3][7].